Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Colossal’s Ben Lamm Says Invasive Species Is a $5.4 Trillion Problem. Here’s His Solution
08:49am, Sunday, 12'th Apr 2026
Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That's according to Ben Lamm, CEO of Colossal Biosciences. On episode 245 of
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 03'rd Apr 2026
CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?
05:28pm, Sunday, 08'th Mar 2026
Intellia Therapeutics is getting around a recent major regulatory setback. However, the stock still faces several potential issues.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 06'th Mar 2026
CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Hold” by Brokerages
05:04am, Friday, 06'th Mar 2026
Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-one analysts that are presently covering the stock, Marketbeat
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
09:07am, Tuesday, 03'rd Mar 2026
Ark Invest bought shares of MercadoLibre, Intellia Therapeutics, and Generate Biomedicines on Monday. MercadoLibre and Intellia Therapeutics are trading 33% and 45% below their 52-week highs, respecti
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial
10:05am, Monday, 02'nd Mar 2026
Intellia Therapeutics Inc. (NASDAQ: NTLA) shares are up on Monday following the FDA's decision to lift the clinical hold on its MAGNITUDE Phase 3 clinical trial.
US FDA lifts clinical hold on Intellia's heart disease gene therapy trial
07:40am, Monday, 02'nd Mar 2026
Intellia Therapeutics said on Monday the U.S. Food and Drug Administration has removed a clinical hold on the late-stage clinical trial for its experimental gene therapy for a heart disease.
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
07:30am, Monday, 02'nd Mar 2026
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
12:15pm, Friday, 27'th Feb 2026
NTLA shares jump after fourth-quarter earnings and revenues exceed expectations. The company focuses on lonvo-z and nex-z pipeline programs.
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
09:47pm, Thursday, 26'th Feb 2026
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
01:16pm, Thursday, 26'th Feb 2026
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to a loss of $1.24 per share a year ago.
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
07:30am, Thursday, 26'th Feb 2026
CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a
Intellia Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 24'th Feb 2026
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
